Fungal infections are a major contributor to infectious disease-related deaths across the
globe. Candida species are among the most common causes of invasive mycotic disease …

Systemic fungal infections pose a serious clinical problem. Treatment options are limited,
and antifungal drug resistance is increasing. In addition, a substantial proportion of patients …

Invasive fungal infections continue to appear in record numbers as the
immunocompromised population of the world increases, owing partially to the increased …

The high clinical mortality and economic burden posed by invasive fungal infections (IFIs),
along with significant agricultural crop loss caused by various fungal species, has resulted in …

Highlights•Our limited arsenal of antifungals is threatened by drug-resistant fungal
pathogens.•Inherent resistance is when all strains of a species show antifungal …

The need for new antifungal agents is undeniable. Current therapeutic choices for the
treatment of invasive fungal infections are limited to three classes of drugs. Most used …

The fungal pathogens Candida albicans, Cryptococcus neoformans, and Aspergillus
fumigatus have transitioned from a rare curiosity to a leading cause of human mortality. The …

The polymorphic fungus Candida albicans is a member of the normal human microbiome. In
most individuals, C. albicans resides as a lifelong, harmless commensal. Under certain …

Antifungal therapy is a central component of patient management for acute and chronic
mycoses. Yet, treatment choices are restricted because of the sparse number of antifungal …

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality,
particularly for patients with compromised immune function. The number of therapeutic …